HCW Biologics (NASDAQ:HCWB) SVP Lee Flowers Acquires 7,736 Shares of Stock

HCW Biologics Inc. (NASDAQ:HCWB) SVP Lee Flowers bought 7,736 shares of HCW Biologics stock in a transaction dated Wednesday, July 29th. The stock was purchased at an average cost of $2.58 per share, for a total transaction of $19,958.88. Following the purchase, the senior vice president owned 8,691 shares of the company’s stock, valued at approximately $22,422.78. This trade represents a 810.05% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

HCW Biologics Trading Up 1.6%

Shares of NASDAQ:HCWB opened at $3.20 on Friday. HCW Biologics Inc. has a 12 month low of $1.50 and a 12 month high of $44.10. The company has a market capitalization of $5.12 million, a price-to-earnings ratio of -0.06 and a beta of 2.29. The firm’s 50-day moving average is $6.50 and its 200 day moving average is $5.20.

HCW Biologics (NASDAQ:HCWB) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.64) by $3.01. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%. The business had revenue of $6.54 million during the quarter, compared to the consensus estimate of $6.54 million.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on HCWB shares. Wall Street Zen upgraded HCW Biologics to a “hold” rating in a report on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research note on Friday, July 17th. Finally, Maxim Group lifted their target price on HCW Biologics from $12.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, HCW Biologics has an average rating of “Hold” and an average target price of $30.00.

Hedge Funds Weigh In On HCW Biologics

A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC purchased a new stake in HCW Biologics Inc. (NASDAQ:HCWB) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). 2.96% of the stock is currently owned by hedge funds and other institutional investors.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.